Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and ...

Early results of a real-world study of faricimab demonstrated sustainable improvements in visual acuity and retinal anatomic ...

This high-tech hearing system came out five years ago but wasn’t available to children under 12 until this year when the FDA lowered the age for implantation to include children over five.

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...

Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution ...

The guacamole, peppers, and vegetables voluntarily recalled by the maker have been classed as the highest risk level by the ...

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

The Supreme Court returns Oct. 7 with a docket featuring cases on transgender rights, gun control, pornography rules, and ...

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

Eli Lilly’s (NYSE:LLY) blockbuster GLP-1 medication, tirzepatide, is no longer in shortage in the U.S., the U.S. Food and ...

Earlier this year, Dutch medical device maker Royal Philips reached a $1.1 billion deal to settle thousands of claims ...

Presidential candidates Kamala Harris and Donald Trump have conflicting views on abortion, IVF, contraceptive, and other ...